Emergent BioSolutions announced that it has signed an agreement to acquire marketing rights to Hikma Pharmaceuticals’ Kloxxado naloxone nasal spray in the US and Canada. Kloxxado, which delivers an 8 mg dose, was approved by the FDA for the reversal of opioid overdose in September 2021. Emergent previously acquired Narcan nasal spray, which delivers a 4 mg dose of naloxone, in 2018 when it acquired Adapt Pharma.
Kloxxado is available by prescription only; Narcan has been approved for over-the-counter sales since March 2023. According to the announcement, Hikma will continue to manufacture Kloxxado, and Emergent will distribute the nasal spray directly to qualified organizations through a web site.
Emergent President and CEO Joe Papa commented, “Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths – Narcan Nasal Spray 4 mg and Kloxxado Nasal Spray 8 mg – allows Emergent to do its part to help save lives from this devastating crisis.”
Read the Emergent BioSolutions press release
